Julien Dagher

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


25 publications

In press | 2024 | 2023 | 2022 | 2021 | 2019 | 2018 | 2017 | 2016 | 2014 | 2013 |
 
Hyperthermic intrathoracic chemotherapy modulates the immune microenvironment of pleural mesothelioma and improves the impact of dual immune checkpoint inhibition.
Hao Y., Gkasti A., Managh A.J., Dagher J., Sifis A., Tiron L., Chriqui L.E., Marie D.N., De Souza Silva O., Christodoulou M. et al. Cancer immunology research. Peer-reviewed.
 
WITHDRAWN: The benefit of adopting Microultrasound in the prostate cancer imaging pathway : A lesion-by-lesion analysis.
Martel P., Rakauskas A., Dagher J., La Rosa S., Meuwly J.Y., Roth B., Valerio M. Progres en urologie. Peer-reviewed.
PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells.
Morotti M., Grimm A.J., Hope H.C., Arnaud M., Desbuisson M., Rayroux N., Barras D., Masid M., Murgues B., Chap B.S. et al., 2024/05. Nature, 629 (8011) pp. 426-434. Peer-reviewed.
 
Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8+ T-myeloid cell networks in melanoma.
Barras D., Ghisoni E., Chiffelle J., Orcurto A., Dagher J., Fahr N., Benedetti F., Crespo I., Grimm A.J., Morotti M. et al., 2024/02/02. Science immunology, 9 (92) pp. eadg7995. Peer-reviewed.
Assessing cancer risk in the anterior part of the prostate using micro-ultrasound: validation of a novel distinct protocol.
Schaer S., Rakauskas A., Dagher J., La Rosa S., Pensa J., Brisbane W., Marks L., Kinnaird A., Abouassaly R., Klein E. et al., 2023/11. World journal of urology, 41 (11) pp. 3325-3331. Peer-reviewed.
The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer.
Kraemer A.I., Chong C., Huber F., Pak H., Stevenson B.J., Müller M., Michaux J., Altimiras E.R., Rusakiewicz S., Simó-Riudalbas L. et al., 2023/05. Nature cancer, 4 (5) pp. 608-628. Peer-reviewed.
Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.
Mark M., Rusakiewicz S., Früh M., Hayoz S., Grosso F., Pless M., Zucali P., Ceresoli G.L., Maconi A., Schneider M. et al., 2022/06. ESMO open, 7 (3) p. 100446. Peer-reviewed.
 
Multiple metastatic clones assessed by an integrative multiomics strategy in clear cell renal carcinoma: a case study.
Dagher J., Brunot A., Evrard B., Kammerer-Jacquet S.F., Beaumont M., Cornevin L., Derquin F., Verhoest G., Bensalah K., Lespagnol A. et al., 2022/06. Journal of clinical pathology, 75 (6) pp. 426-430. Peer-reviewed.
 
The benefit of adopting Microultrasound in the prostate cancer imaging pathway: A lesion-by-lesion analysis: Biopsies prostatiques guidée par micro-échographie, quel bénéfice ? Une analyse lésion par lésion.
Martel P., Rakauskas A., Dagher J., La Rosa S., Meuwly J.Y., Roth B., Valerio M., 2022/06. Progres en urologie, 32 (6S1) pp. 6S26-6S32. Peer-reviewed.
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
Bruand M., Barras D., Mina M., Ghisoni E., Morotti M., Lanitis E., Fahr N., Desbuisson M., Grimm A., Zhang H. et al., 2021/07/20. Cell reports, 36 (3) p. 109412. Peer-reviewed.
Rate of Freeze Impacts the Survival and Immune Responses Post Cryoablation of Melanoma.
Yakkala C., Dagher J., Sempoux C., Chiang C.L., Denys A., Kandalaft L.E., Koppolu B., Duran R., 2021/06/03. Frontiers in immunology, 12 p. 695150. Peer-reviewed.
 
Is the UICC/AJCC pT2 Staging Category for Clear Cell Renal Cell Carcinoma Meaningful?
Delahunt B., Dagher J., Egevad L., Yaxley J., Varma M., Samaratunga H., 2019/09. The American journal of surgical pathology, 43 (9) pp. 1249-1252. Peer-reviewed.
 
Percentage grade 4 tumour predicts outcome for clear cell renal cell carcinoma.
Dagher J., Delahunt B., Rioux-Leclercq N., Egevad L., Varma M., Samaratunga H., 2019/06. Pathology, 51 (4) pp. 349-352. Peer-reviewed.
 
Assessment of tumour-associated necrosis provides prognostic information additional to World Health Organization/International Society of Urological Pathology grading for clear cell renal cell carcinoma.
Dagher J., Delahunt B., Rioux-Leclercq N., Egevad L., Coughlin G., Dunglison N., Gianduzzo T., Kua B., Malone G., Martin B. et al., 2019/01. Histopathology, 74 (2) pp. 284-290. Peer-reviewed.
 
Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques.
Yaxley J.W., Dagher J., Delahunt B., Egevad L., Srigley J., Samaratunga H., 2018/01. World journal of urology, 36 (1) pp. 15-20. Peer-reviewed.
 
Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading.
Dagher J., Delahunt B., Rioux-Leclercq N., Egevad L., Srigley J.R., Coughlin G., Dunglinson N., Gianduzzo T., Kua B., Malone G. et al., 2017/12. Histopathology, 71 (6) pp. 918-925. Peer-reviewed.
 
Clear cell renal cell carcinoma: a comparative study of histological and chromosomal characteristics between primary tumors and their corresponding metastases.
Dagher J., Kammerer-Jacquet S.F., Dugay F., Beaumont M., Lespagnol A., Cornevin L., Verhoest G., Bensalah K., Rioux-Leclercq N., Belaud-Rotureau M.A., 2017/07. Virchows Archiv, 471 (1) pp. 107-115. Peer-reviewed.
 
Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype.
Kammerer-Jacquet S.F., Brunot A., Pladys A., Bouzille G., Dagher J., Medane S., Peyronnet B., Mathieu R., Verhoest G., Bensalah K. et al., 2017/02. Clinical genitourinary cancer, 15 (1) pp. e1-e7. Peer-reviewed.
 
Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential.
Kammerer-Jacquet S.F., Crouzet L., Brunot A., Dagher J., Pladys A., Edeline J., Laguerre B., Peyronnet B., Mathieu R., Verhoest G. et al., 2017/01/01. International journal of cancer, 140 (1) pp. 142-148. Peer-reviewed.
 
An unusual case of adrenocortical carcinoma with liver metastasis that occurred at 23 years after surgery.
Bergeat D., Rayar M., Beuzit L., Levi Sandri G.B., Dagher J., Merdrignac A., Tanguy L., Boudjema K., Sulpice L., Meunier B., 2016/06. Hepatobiliary surgery and nutrition, 5 (3) pp. 265-268. Peer-reviewed.
 
Wild-type VHL Clear Cell Renal Cell Carcinomas Are a Distinct Clinical and Histologic Entity: A 10-Year Follow-up.
Dagher J., Kammerer-Jacquet S.F., Brunot A., Pladys A., Patard J.J., Bensalah K., Perrin C., Verhoest G., Mosser J., Lespagnol A. et al., 2016/02. European urology focus, 1 (3) pp. 284-290. Peer-reviewed.
 
Cytoplasmic PAR-3 protein expression is associated with adverse prognostic factors in clear cell renal cell carcinoma and independently impacts survival.
Dagher J., Dugay F., Rioux-Leclercq N., Verhoest G., Oger E., Bensalah K., Cabillic F., Jouan F., Kammerer-Jacquet S.F., Fergelot P. et al., 2014/08. Human pathology, 45 (8) pp. 1639-1646. Peer-reviewed.
 
Cytogénétique des carcinomes rénaux [Cytogenetics profiles of renal carcinoma]
Dugay F., Dagher J., Verhoest G., Henry C., Jaillard S., Arlot-Bonnemains Y., Bensalah K., Vigneau C., Rioux-Leclercq N., Belaud-Rotureau M.A., 2014/03. Morphologie, 98 (320) pp. 1-7. Peer-reviewed.
 
Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.
Cabillic F., Gros A., Dugay F., Begueret H., Mesturoux L., Chiforeanu D.C., Dufrenot L., Jauffret V., Dachary D., Corre R. et al., 2014/03. Journal of thoracic oncology, 9 (3) pp. 295-306. Peer-reviewed.
 
Histologic prognostic factors associated with chromosomal imbalances in a contemporary series of 89 clear cell renal cell carcinomas.
Dagher J., Dugay F., Verhoest G., Cabillic F., Jaillard S., Henry C., Arlot-Bonnemains Y., Bensalah K., Oger E., Vigneau C. et al., 2013/10. Human pathology, 44 (10) pp. 2106-2115. Peer-reviewed.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Swiss University